Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $2.50. The current price Evelo Biosciences (EVLO) is trading at is $2.19, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 14.16% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 82.65% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 128.31% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 128.31% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 1794.98% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 447.95% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 1635.16% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 1178.54% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 493.61% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 721.92% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 539.27% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1132.88% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 173.97% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 265.3% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 858.9% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 173.97% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 721.92% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 356.62% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 1224.2% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 1041.55% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 1087.21% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/16/2022 | 14.16% | 查尔丹资本 | → $2.5 | 评级下调 | 购买→中性 |
| 09/09/2022 | 82.65% | 摩根士丹利 | $5 → $4 | 维护 | 等重 |
| 08/24/2022 | 128.31% | 摩根士丹利 | $6 → $5 | 维护 | 等重 |
| 08/15/2022 | 128.31% | 查尔丹资本 | $12 → $5 | 维护 | 买 |
| 11/02/2021 | 1794.98% | JMP证券 | $44 → $41.5 | 维护 | 市场表现强于大盘 |
| 11/01/2021 | 447.95% | 查尔丹资本 | → $12 | 升级 | 中性→购买 |
| 06/23/2021 | 1635.16% | JMP证券 | $36 → $38 | 维护 | 市场表现强于大盘 |
| 06/23/2021 | 1178.54% | 康托·菲茨杰拉德 | → $28 | 开始承保 | →超重 |
| 05/03/2021 | 493.61% | 摩根士丹利 | $14 → $13 | 维护 | 等重 |
| 04/12/2021 | 721.92% | 杰富瑞 | $11 → $18 | 升级 | 持有→购买 |
| 01/19/2021 | 539.27% | 摩根士丹利 | $6 → $14 | 维护 | 等重 |
| 12/23/2020 | 1132.88% | JMP证券 | → $27 | 开始承保 | →跑赢大盘 |
| 11/11/2020 | 173.97% | 摩根士丹利 | $8 → $6 | 维护 | 等重 |
| 05/21/2020 | 265.3% | 摩根士丹利 | → $8 | 评级下调 | 超重→等重 |
| 05/12/2020 | 858.9% | 蒙特利尔银行资本 | $24 → $21 | 维护 | 跑赢大盘 |
| 05/12/2020 | 173.97% | 杰富瑞 | $18 → $6 | 评级下调 | 购买→Hold |
| 04/30/2019 | 721.92% | 杰富瑞 | → $18 | 开始承保 | →购买 |
| 01/29/2019 | 356.62% | 查尔丹资本 | → $10 | 开始承保 | →中性 |
| 10/12/2018 | 1269.86% | 摩根士丹利 | $29 → $30 | 维护 | 超重 |
| 10/11/2018 | 1269.86% | 摩根士丹利 | $29 → $30 | 维护 | 超重 |
| 06/04/2018 | 1224.2% | 摩根士丹利 | → $29 | 开始承保 | →超重 |
| 06/04/2018 | — | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 06/04/2018 | 1041.55% | JMP证券 | → $25 | 开始承保 | →跑赢大盘 |
| 06/04/2018 | 1087.21% | 蒙特利尔银行资本 | → $26 | 开始承保 | →跑赢大盘 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的目标价格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Chardan Capital on November 16, 2022. The analyst firm set a price target for $2.50 expecting EVLO to rise to within 12 months (a possible 14.16% upside). 4 analyst firms have reported ratings in the last year.
查尔丹资本于2022年11月16日报道了Evelo Biosciences(纳斯达克：EVLO)的最新目标价。这家分析公司将目标价定为2.50美元，预计EVLO将在12个月内升至(可能上涨14.16%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的最新分析师评级是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Chardan Capital, and Evelo Biosciences downgraded their neutral rating.
Evelo Biosciences(纳斯达克：EVLO)的最新分析师评级由查尔丹资本提供，Evelo Biosciences下调了中性评级。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Evelo Biosciences的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Evelo Bioscience的上一次评级是在2022年11月16日提交的，所以你应该预计下一次评级将在2023年11月16日左右提供。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析师对Evelo Biosciences(EVLO)的评级正确吗？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $2.50. The current price Evelo Biosciences (EVLO) is trading at is $2.19, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Evelo Biosciences(EVLO)评级被下调，目标价为0.00美元至2.50美元。Evelo Biosciences(EVLO)目前的交易价格为2.19美元，在分析师的预测范围内。
